Cargando…
Utility of Clinical–Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions
PURPOSE: To determine the predictive performance of the integrated model based on clinical factors and radiomic features for the accurate identification of clinically significant prostate cancer (csPCa) among Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions. MATERIALS AND METHODS: A re...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913337/ https://www.ncbi.nlm.nih.gov/pubmed/35280813 http://dx.doi.org/10.3389/fonc.2022.840786 |
_version_ | 1784667416182128640 |
---|---|
author | Jin, Pengfei Yang, Liqin Qiao, Xiaomeng Hu, Chunhong Hu, Chenhan Wang, Ximing Bao, Jie |
author_facet | Jin, Pengfei Yang, Liqin Qiao, Xiaomeng Hu, Chunhong Hu, Chenhan Wang, Ximing Bao, Jie |
author_sort | Jin, Pengfei |
collection | PubMed |
description | PURPOSE: To determine the predictive performance of the integrated model based on clinical factors and radiomic features for the accurate identification of clinically significant prostate cancer (csPCa) among Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions. MATERIALS AND METHODS: A retrospective study of 103 patients with PI-RADS 3 lesions who underwent pre-operative 3.0-T MRI was performed. Patients were randomly divided into the training set and the testing set at a ratio of 7:3. Radiomic features were extracted from axial T2WI, diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) images of each patient. The minimum redundancy maximum relevance (mRMR) and least absolute shrinkage and selection operator (LASSO) feature selection methods were used to identify the radiomic features and construct a radiomic model for csPCa identification. Moreover, multivariable logistic regression analysis was used to integrate the clinical factors with radiomic feature model to further improve the accuracy of csPCa identification, and the two are presented in the form of normogram. The performance of the integrated model was compared with radiomic model and clinical model on testing set. RESULTS: A total of four radiomic features were selected and used for radiomic model construction producing a radiomic score (Radscore). Radscore was significantly different between the csPCa and the non-csPCa patients (training set: p < 0.001; testing set: p = 0.035). Multivariable logistic regression analysis showed that age and PSA could be used as independent predictors for csPCa identification. The clinical–radiomic model produced the receiver operating characteristic (ROC) curve (AUC) in the testing set was 0.88 (95%CI, 0.75–1.00), which was similar to clinical model (AUC = 0.85; 95%CI, 0.52–0.90) (p = 0.048) and higher than the radiomic model (AUC = 0.71; 95%CI, 0.68–1.00) (p < 0.001). The decision curve analysis implies that the clinical–radiomic model could be beneficial in identifying csPCa among PI-RADS 3 lesions. CONCLUSION: The clinical–radiomic model could effectively identify csPCa among biparametric PI-RADS 3 lesions and thus could help avoid unnecessary biopsy and improve the life quality of patients. |
format | Online Article Text |
id | pubmed-8913337 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89133372022-03-12 Utility of Clinical–Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions Jin, Pengfei Yang, Liqin Qiao, Xiaomeng Hu, Chunhong Hu, Chenhan Wang, Ximing Bao, Jie Front Oncol Oncology PURPOSE: To determine the predictive performance of the integrated model based on clinical factors and radiomic features for the accurate identification of clinically significant prostate cancer (csPCa) among Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions. MATERIALS AND METHODS: A retrospective study of 103 patients with PI-RADS 3 lesions who underwent pre-operative 3.0-T MRI was performed. Patients were randomly divided into the training set and the testing set at a ratio of 7:3. Radiomic features were extracted from axial T2WI, diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) images of each patient. The minimum redundancy maximum relevance (mRMR) and least absolute shrinkage and selection operator (LASSO) feature selection methods were used to identify the radiomic features and construct a radiomic model for csPCa identification. Moreover, multivariable logistic regression analysis was used to integrate the clinical factors with radiomic feature model to further improve the accuracy of csPCa identification, and the two are presented in the form of normogram. The performance of the integrated model was compared with radiomic model and clinical model on testing set. RESULTS: A total of four radiomic features were selected and used for radiomic model construction producing a radiomic score (Radscore). Radscore was significantly different between the csPCa and the non-csPCa patients (training set: p < 0.001; testing set: p = 0.035). Multivariable logistic regression analysis showed that age and PSA could be used as independent predictors for csPCa identification. The clinical–radiomic model produced the receiver operating characteristic (ROC) curve (AUC) in the testing set was 0.88 (95%CI, 0.75–1.00), which was similar to clinical model (AUC = 0.85; 95%CI, 0.52–0.90) (p = 0.048) and higher than the radiomic model (AUC = 0.71; 95%CI, 0.68–1.00) (p < 0.001). The decision curve analysis implies that the clinical–radiomic model could be beneficial in identifying csPCa among PI-RADS 3 lesions. CONCLUSION: The clinical–radiomic model could effectively identify csPCa among biparametric PI-RADS 3 lesions and thus could help avoid unnecessary biopsy and improve the life quality of patients. Frontiers Media S.A. 2022-02-24 /pmc/articles/PMC8913337/ /pubmed/35280813 http://dx.doi.org/10.3389/fonc.2022.840786 Text en Copyright © 2022 Jin, Yang, Qiao, Hu, Hu, Wang and Bao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Jin, Pengfei Yang, Liqin Qiao, Xiaomeng Hu, Chunhong Hu, Chenhan Wang, Ximing Bao, Jie Utility of Clinical–Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions |
title | Utility of Clinical–Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions |
title_full | Utility of Clinical–Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions |
title_fullStr | Utility of Clinical–Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions |
title_full_unstemmed | Utility of Clinical–Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions |
title_short | Utility of Clinical–Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions |
title_sort | utility of clinical–radiomic model to identify clinically significant prostate cancer in biparametric mri pi-rads v2.1 category 3 lesions |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913337/ https://www.ncbi.nlm.nih.gov/pubmed/35280813 http://dx.doi.org/10.3389/fonc.2022.840786 |
work_keys_str_mv | AT jinpengfei utilityofclinicalradiomicmodeltoidentifyclinicallysignificantprostatecancerinbiparametricmripiradsv21category3lesions AT yangliqin utilityofclinicalradiomicmodeltoidentifyclinicallysignificantprostatecancerinbiparametricmripiradsv21category3lesions AT qiaoxiaomeng utilityofclinicalradiomicmodeltoidentifyclinicallysignificantprostatecancerinbiparametricmripiradsv21category3lesions AT huchunhong utilityofclinicalradiomicmodeltoidentifyclinicallysignificantprostatecancerinbiparametricmripiradsv21category3lesions AT huchenhan utilityofclinicalradiomicmodeltoidentifyclinicallysignificantprostatecancerinbiparametricmripiradsv21category3lesions AT wangximing utilityofclinicalradiomicmodeltoidentifyclinicallysignificantprostatecancerinbiparametricmripiradsv21category3lesions AT baojie utilityofclinicalradiomicmodeltoidentifyclinicallysignificantprostatecancerinbiparametricmripiradsv21category3lesions |